| 000 | 01836 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250516222439.0 | ||
| 264 | 0 | _c20140902 | |
| 008 | 201409s 0 0 eng d | ||
| 022 | _a1554-6578 | ||
| 024 | 7 |
_a10.1097/NEN.0000000000000095 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTatenhorst, Lars | |
| 245 | 0 | 0 |
_aRho kinase inhibition by fasudil in the striatal 6-hydroxydopamine lesion mouse model of Parkinson disease. _h[electronic resource] |
| 260 |
_bJournal of neuropathology and experimental neurology _cAug 2014 |
||
| 300 |
_a770-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_a1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aAdrenergic Agents _xtoxicity |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aApomorphine |
| 650 | 0 | 4 |
_aCorpus Striatum _xdrug effects |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 |
_aDopamine _xmetabolism |
| 650 | 0 | 4 |
_aDopamine Plasma Membrane Transport Proteins _xmetabolism |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Inbred C57BL |
| 650 | 0 | 4 |
_aMotor Activity _xdrug effects |
| 650 | 0 | 4 |
_aMuscle Strength _xdrug effects |
| 650 | 0 | 4 |
_aOxidopamine _xtoxicity |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aSubstantia Nigra _xpathology |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aTyrosine 3-Monooxygenase _xmetabolism |
| 700 | 1 | _aTönges, Lars | |
| 700 | 1 | _aSaal, Kim-Ann | |
| 700 | 1 | _aKoch, Jan C | |
| 700 | 1 | _aSzegő, Éva M | |
| 700 | 1 | _aBähr, Mathias | |
| 700 | 1 | _aLingor, Paul | |
| 773 | 0 |
_tJournal of neuropathology and experimental neurology _gvol. 73 _gno. 8 _gp. 770-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/NEN.0000000000000095 _zAvailable from publisher's website |
| 999 |
_c23989117 _d23989117 |
||